NCT01440920

A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients

A Phase I Study of OCV-501 in the Treatment of Patients With Acute Myeloid Leukemia

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Otsuka Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety, tolerability of OCV-501 in patients with acute myeloid leukemia (AML) who achieved complete remission after induction regimen and who completed a standard consolidation therapy.

Conditions

• Acute Myeloid Leukemia

Interventions

Type	Name	Description
DRUG	OCV-501	subcutaneously administered once a week, 4 times at the dose of 0.3 mg
DRUG	OCV-501	subcutaneously administered once a week, 4 times at the dose of 1 mg
DRUG	OCV-501	subcutaneously administered once a week, 4 times at the dose of 3 mg

Timeline

• Start date: 2011-09-01
• Primary completion: 2013-03-01
• Completion: 2013-07-01
• First posted: 2011-09-27
• Last updated: 2021-03-08
• Results posted: 2021-03-08

Locations

1 site across 1 country: Japan